Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.65 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8216879 | 0.83 | TAAR1 (0.60) | HRH3TAAR1ADRA2C | |
| SCHEMBL8211595 | 0.78 | TAAR1 (0.70) | HRH3TAAR1ADRA2C | |
| SCHEMBL6712626 | 0.77 | HRH3 (0.45) | HRH3TAAR1 | |
| SCHEMBL4901454 | 0.77 | TAAR1 (1.00) | HRH3TAAR1ADRA2CADRA1DADRA1A | |
| SCHEMBL14189389 | 0.75 | TAAR1 (0.87) | HRH3TAAR1ADRA2CADRA1DADRA1A | |
| SCHEMBL25039331 | 0.74 | HRH3 (0.74) | HRH3TAAR1ADRA2C | |
| SCHEMBL8213480 | 0.71 | TAAR1 (0.59) | HRH3TAAR1 | |
| SCHEMBL10228943 | 0.71 | TAAR1 (0.59) | HRH3TAAR1ADRA2CADRA1DADRA1A | |
| SCHEMBL8216334 | 0.71 | TAAR1 (0.59) | HRH3TAAR1ADRA2C | |
| SCHEMBL631816 | 0.70 | HRH3 (0.39) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586617-B2 | Aminomethyl-4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2076497-B1 | AMINOMETHYL-4-IMIDAZOLES | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-22 | — | — | US | disclosed |
| WO-2008046757-A1 | AMINOMETHYL-4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | INMT, HTR4, MC4R | HRH3 728/4885TAAR1 419/4885ADRA2C 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.